scholarly journals Clinical experience with a fixed dose combination therapy of timolol and pilocarpine used twice daily in the management of chronic open angle glaucoma

Eye ◽  
1994 ◽  
Vol 8 (4) ◽  
pp. 410-413 ◽  
Author(s):  
A P Moriarty ◽  
T C Dowd ◽  
R B Trimble
2021 ◽  
Author(s):  
Ulrich Thelen

Abstract Background: To evaluate the effect of an "escalation" of topical glaucoma therapy by switching form prostaglandin monotherapy to two different prostaglandin-timolol fixed combinations.Methods: 30 patients (60 eyes) with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) were initially treated with the prostaglandin analog latanoprost in a preservative-free formulation. 15 patients each were for 6 months - because of IOP levels considered still too high - treated with preservative-free tafluprost/timolol fixed-dose combination or preservative-free latanoprost/timolol fixed-dose combination therapy. Results: Six months after switching from latanopost monotherapy to preservative-free prostaglandin-timolol combinations, patients being treated with the latanoprost-timolol fixed combination had a mean IOP reduction by 4.16 mm Hg and those treated with the tafluprost-timolol fixed combination a mean IOP reduction by 5.38 mm Hg. Regarding safety and tolerability, there were no issues in the tafluprost-timolol group.Conclusions: Switching from prostaglandin monotherapy to a prostaglandin-timolol fixed combination led to a sufficient IOP lowering in our group of patients. Tolerability of, and satisfaction with, the fixed combination therapies was high.


Author(s):  
Munib ur Rehman ◽  
Shahid Mehmood Diyal ◽  
Bilal Humayun Mirza ◽  
Iqra Qureshi ◽  
Muhammad Rizwan Ullah

Background: Glaucoma is the cause of blindness. Beta blocker and prostaglandins are used as a first line treatment of open angle glaucoma. The exact target with mono therapy for reducing intraocular pressure is achieved within 2 years, so patient prefers fixed dose combination therapy. Objective: For reducing intraocular pressure efficacy, travoprost mono therapy and timolol/brinzolamide fixed dose combination therapy is compared. Material and methods: For 3 months, patients are randomly received 0.5% timolol and 0.2% brinzolamide twice daily and travporost once daily 0.004%.Then compared intraocular pressure, pulse rate, blood pressure, and cup disc ratio over 12 weeks of treatment. Results: 27.99% and 30.49% reduction in intraocular pressure is observed with mono therapy and fixed dose combination respectively. Pulse rate (9beats/min) and systolic pressure reduction by (2.35mmHg) were seen with fixed dose combination but no cup disc ratio observed. Conclusion: It is proved that 0.5% timolol and 0.2% brinzolamide causes more reduction in intraocular pressure than the 0.004% travporost mono therapy. Keywords: Glaucoma, travporost and lantoprost


2020 ◽  
Vol 12 ◽  
pp. 251584142090966
Author(s):  
Alok Dixit ◽  
Atul Ashish ◽  
Reena Sharma

Background: Glaucoma is most common irreversible cause of blindness in India. First line management of open-angle glaucoma is either beta blockers or prostaglandin analogs monotherapy. Monotherapy rarely achieves target intraocular pressure within 2 years and patients are shifted to combination medications, usually fixed-dose combination. Objective: To compare travoprost monotherapy and timolol/brinzolamide fixed-dose combination for their intraocular pressure lowering efficacy, their effects on hemodynamic parameters and cup disc ratio reversibility in newly diagnosed drug-naïve open-angle glaucoma patients. Material and methods: In a 12-week, prospective, randomised, single-blind study, patients were randomised to receive twice daily 0.5% timolol and 0.2% brinzolamide fixed-dose combination (n = 52) or once daily travoprost 0.004% (n = 52). Intraocular pressure, blood pressure, pulse rate and cup disc ratio were compared across treatment groups over 3 months. Results: Significant reduction ( p < 0.001) in intraocular pressure by 27.99% and 30.49% at 12th-week visit as compared with baseline was observed in monotherapy and fixed-dose combination group, respectively. Significant changes in pulse rate (9 beats/min) and systolic blood pressure (2.35 mmHg) was observed in fixed-dose combination group. No cup disc ratio reversibility was observed at the end of study. Conjunctival hyperaemia ( n = 14) and transient blurring of vision ( n = 16) were most commonly reported adverse drug reaction in monotherapy and fixed-dose combination, respectively. Conclusion: The 0.5% timolol and 0.2% brinzolamide fixed-dose combination produced greater reduction in intraocular pressure than those produced by 0.004% travoprost alone in drug-naïve open-angle glaucoma patients.


Author(s):  
Deepalatha C ◽  
Leela Pratyusha Mb

Objective: To study the drug utilization pattern in patients suffering from primary open-angle glaucoma (POAG) in a tertiary care teaching hospital.Methods: It is a prospective study done on 50 patients of POAG (comprising of individuals belonging to any age group). This study was carried for a period of 2-month, and the data included patient’s demographic details and the drugs prescribed. Data were analyzed for drug use pattern.Results: After screening the prescriptions of patients, it was found out that out of total 50 prescriptions, 30 were males, and 20 were females. Out of50 prescriptions, prostaglandins (58%) were most commonly prescribed. β-blockers (16%) were also prescribed. Fixed dose combination constituted60% of the prescriptions. Instructions about the route, frequency, and duration of treatment were present in all prescriptions. Drugs prescribed by their generic names were 18.75% and about 81.25% of the drugs were prescribed by their brand names.Conclusions: Fixed drug combination of timolol and dorzolamide was the most frequently prescribed combination. Prescribers must be aware ofimportance of prescribing drugs with generic names.Keywords: Primary open-angle glaucoma, Intraocular pressure, Fixed dose combination.


Sign in / Sign up

Export Citation Format

Share Document